SCHEMBL766749

SCHEMBL766749

COCC[Si](OC)(OC)OC

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445035 0.81 LMNA (0.40) LMNA
SCHEMBL6138643 0.80 LMNA (0.33) LMNA
SCHEMBL12532431 0.79 LMNA (0.39) LMNA
SCHEMBL35673 0.78 LMNA (0.39) LMNA
SCHEMBL22092444 0.78 LMNA (0.39) LMNA
SCHEMBL4932454 0.77 LMNA (0.42) LMNA
SCHEMBL16746517 0.77 LMNA (0.42) LMNA
SCHEMBL22806611 0.77 LMNA (0.42) LMNA
SCHEMBL10115033 0.75
SCHEMBL28395575 0.75 LMNA (0.31) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526306-A1 PHOTOCHROMIC ARTICLE SDC Technologies, Inc. (US) 2019-08-21 EP disclosed
WO-2019067838-A1 PHOTOCHROMIC ARTICLE SDC TECHNOLOGIES, INC. (US) 2019-04-04 WO disclosed
US-20170114247-A1 PROCESSES FOR MOISTURE SCAVENGING IN PREPARING POLYURETHANE COATINGS AND COMPOSITIONS THEREFOR Achiewell, LLC 2017-04-27 US disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
EP-2454246-A2 SOLVATES OF DOCETAXEL Przedsiebiorstwo Produkcyjno-Wdrozeniowe (PL) 2012-05-23 EP disclosed
US-20120071674-A1 SOLVATES OF DOCETAXEL PRZEDSIEBIORSTWO PRODUKCYJNO-WDROZENIOWE IFOTAM SP. Z O.O. (PL) 2012-03-22 US disclosed
WO-2010138010-A2 SOLVATES OF 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11 -EN- 13α-YL (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE Przedsiębiorstwo Produkcyjno-Wdrożeniowe (PL) 2010-12-02 WO disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
EP-2001965-A1 COATING COMPOSITIONS, ARTICLES, AND METHODS OF COATING ARTICLES SDC COATINGS, INC. (US) 2008-12-17 EP disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1099703-B1 Process for preparing alkoxysilanes DEGUSSA (DE) 2004-08-11 EP disclosed
WO-2004033573-A1 FLEXIBLE EMISSIVE COATINGS FOR ELASTOMER SUBSTRATES LORD CORPORATION (US) 2004-04-22 WO disclosed
EP-0997468-B1 Process for neutralising or reducing chlorine content of alkoxy silanes or alkoxysilane-based compositions DEGUSSA (DE) 2004-01-21 EP disclosed
US-6323356-B1 REACTING HALOGENOSILANE WITH ALCOHOL IN THE PRESENCE OF METALLIC MAGNESIUM TO FORM A CRUDE PRODUCT; ISOLATING AN ALKOXYSILANE DEGUSSA-HUELS AKTIENGESELLSCHAFT (DE) 2001-11-27 US disclosed
EP-1099703-A2 Process for preparing alkoxysilanes Degussa AG (DE) 2001-05-16 EP disclosed
US-6177584-B1 Process for neutralizing and reducing residual halogen contents in alkoxysilanes or alkoxysilane-based compositions DEGUSSA-HUELS AKTIENGESELLSCHAFT (DE) 2001-01-23 US disclosed
EP-0997468-A2 Process for neutralising or reducing chlorine content of alkoxy silanes or alkoxysilane-based compositions Degussa-Hüls Aktiengesellschaft (DE) 2000-05-03 EP disclosed
EP-0378430-B1 Novel organosilicon compound and process for producing organosilicon compound AGENCY IND SCIENCE TECHN (JP) 1995-02-01 EP disclosed
US-5151538-A ORGANOSILICON COMPOUND AND PROCESS FOR PRODUCING ORGANOSILICON COMPOUND AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1992-09-29 US disclosed
EP-0378430-A1 Novel organosilicon compound and process for producing organosilicon compound DIRECTOR-GENERAL OF THE AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1990-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071674-A1 SOLVATES OF DOCETAXEL TERT, TBCA, TAF11 LMNA 3065/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 LMNA 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.